Objectives This study sought to evaluate long-term survival in type B aortic dissection patients treated with thoracic endovascular aortic repair (TEVAR) therapy.
Thoracic endovascular aortic repair (TEVAR) is an emerging strategy in the treatment of descending aortic disease (1) (2) (3) (4) . Initial studies demonstrated the technical feasibility and relative safety of endovascular approaches, even in the difficult clinical scenario of complicated type B acute aortic dissection (TBAAD) (5) (6) (7) (8) (9) (10) (11) (12) . However, survival data are limited by small case series or short follow-up periods. Furthermore, a randomized study of descending aortic dissection in the subacute phase failed to demonstrate any survival benefit to TEVAR compared with medical therapy at 2 years after treatment (13) . We utilized the resources of IRAD (the International Registry of Acute Aortic Dissection) to analyze the long-term outcomes of patients with TBAAD treated with an endovascular technique compared with those undergoing medical management alone.
Methods
IRAD is a multinational registry of 24 referral centers in 12 countries, designed to provide an unbiased representative population of patients with acute aortic dissection. Full details of the IRAD methods and registry structure have been previously described (14) (15) (16) (17) (18) (19) . Data were obtained from hospital records of 3,865 patients enrolled in IRAD with acute aortic dissection between December 26, 1995 , and January 20, 2012, 1,333 of whom were classified as TBAAD. A full list of IRAD contributors is provided in the Online Appendix. Study population. In IRAD, patients were identified prospectively at the time of presentation or retrospectively from discharge diagnosis, and from imaging and surgical databases. The study population consisted of 1,129 patients with TBAAD enrolled in IRAD between December 26, 1995, and January 20, 2012 , who underwent either medical therapy (n ¼ 853, 74.8%) or endovascular stent-graft placement (n ¼ 276, 25.2%) in addition to medical therapy (Table 1) . Specifics regarding endovascular technique were available in 138 patients, some of whom had multiple stents, and consisted of stent-graft placement in the descending aorta (n ¼ 100) and/ or in the abdominal aorta (n ¼ 48) using a commercially available stent graft with or without percutaneous fenestration (n ¼ 39) or peripheral vessel stenting (n ¼ 39), according to standard methods (Table 2) . Patients with TBAAD subjected to open surgical repair during the acute phase (183, 13.6%) were not considered in this analysis. Diagnosis was based on confirmatory imaging at each center. A total of 1,025 patients were discharged alive, and 580 (56.6%) had consecutive follow-up data available. When looking at variables from the initial hospitalization, patients with follow-up data available were more likely to be male, have an abnormal chest x-ray without associated pain, and were more likely to have angiotensin-converting enzyme inhibitors prescribed at discharge. Additionally, these patients had significantly more in-hospital stroke, larger descending aortic diameters, and longer length of stay. Conversely, patients who were lost to follow-up were more 
Survival After Acute Type B Dissection likely to have a history of percutaneous coronary intervention and to present with anterior chest pain. No other differences among in-hospital variables were seen between patients who had follow-up data reported and those who did not. In patients who had follow-up, their respective follow-up periods were defined as the portion of time for which each patient had consecutive data available starting 1 year from the incident event.
Data collection. Data were collected on standardized forms with standard IRAD definitions. Information on 290 clinical variables was collected, including patient demographics, medical history, clinical presentation, physical findings, imaging studies, details of medical and endovascular management, in-hospital clinical events, length of stay, and in-hospital mortality. Yearly follow-up data were obtained up to 5 years after discharge with standardized forms. Data forms were entered into an online database maintained by the IRAD coordinating center at the University of Michigan. Statistical analysis. Data are shown as frequencies and percentages and as mean AE SD. Missing data were not defaulted to negative, and denominators reflect only reported cases. Associations of death among nominal variables were compared using the chi-square test or Fisher exact test when appropriate, and among continuous variables, using the Student t test. Kaplan-Meier analysis was used for follow-up data. Only patients with consecutive follow-up, beginning at 1 year, were included in the analysis. Because patients were not randomly assigned to the 2 treatment groups, a propensity model utilizing a multivariable binary logistic regression was developed to generate a propensity score from the conditional probability computed for endovascular treatment versus medical treatment. The Hosmer-Lemeshow test p value was 0.261, with a c-statistic of 0.725. A propensity-matched dataset was then created, matching the propensity score for patients undergoing endovascular treatment with the propensity score for patients undergoing medical treatment only. A 2:1 matching scheme was utilized for the control group (medical management only) versus the treatment group (endovascular procedure). Chi-square or Fischer exact tests were performed to evaluate differences between the 2 groups regarding in-hospital and Values are n (%).
Figure 1. Maximum Diameter of the Descending Aorta
The diameter of the aortas of patients treated with thoracic endovascular aortic repair are compared with those of patients managed medically at the following time points: in-hospital and at 1 and 5 years post-discharge.
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follow-up outcomes, which were similar between management types for all variables considered.
Results
Clinical characteristics at presentation and in-hospital outcome. Among patients in IRAD with TBAAD (1,129 patients), 853 (74.8%) patients were initially treated medically, and 276 (25.2%) were managed using an endovascular approach. There were several significant differences in the demographic statistics between the 2 groups ( (Fig. 1) . In-hospital mortality was similar in patients subjected to endovascular repair (10.9% vs. 8.7%, p ¼ 0.273), as compared with those under medical treatment alone (Table 3) . Post-procedure, only 2 endovascular patients (0.8%) developed spinal cord ischemia who did not have the condition on presentation. Complications during the acute phase (renal failure, cerebrovascular accidents, spinal cord ischemia, extension of dissection) occurred in 204 patients (22.7%) and were more common in patients submitted to TEVAR compared with patients given medication alone (38.9% vs. 17.8%). One-year follow-up. Five hundred eighty patients were discharged alive with documented clinical follow-up data. Mortality at 1-year post-discharge was 8.1% in patients previously treated with endovascular stent grafts and 9.8% Values are n (%) or median (interquartile range).
Figure 2. Kaplan-Meier Survival Estimates
Patients with type B dissection subjected to thoracic endovascular aortic repair are compared with those treated with medical therapy alone.
for patients with medical therapy alone ( (Fig. 1) .
Long-term follow-up. Kaplan-Meier survival estimates at 5 years showed that patients subjected to endovascular treatment had a lower death rate (15.5% vs. 29.0%, p ¼ 0.018) (Fig. 2) . Five-year estimates for late intervention were 30.6% after TEVAR versus 19.7% in medically managed patients (p ¼ 0.810). Low incidence of stent-graft migration (6.6%) and endoleak (13.4%) was observed after initial TEVAR (Table 5 ). Extension of dissection or new dissections were identified in 12.2% of TEVAR patients versus 15.9% with medical management (p ¼ 0.888) (Fig. 3) . Interestingly, although no significant difference in diameter of the descending aorta was present at 1 year in both groups, at 5 years, the diameter of the descending aorta was significantly smaller after stent graft as compared with medical therapy alone (median, 4.6 [IQR: 3.6 to 5.5] cm medical therapy vs. median, 4.2 [IQR: 3.8 to 5.2] cm TEVAR, p ¼ 0.034) (Fig. 1) .
Discussion
The appropriate treatment strategy for descending aortic dissection has long been a matter of debate. For many years, there was a consensus that patients with type B dissections should be medically treated unless life-threatening complications occurred. However, the long-term prognosis of untreated chronic type B dissection is sobering, with survival estimates at 5 years ranging from just 60% to 80% (20) (21) (22) (23) (24) (25) (26) (27) .
Once the aortic diameter exceeds 60 mm, the risk of rupture is estimated at 30% per annum (20) . Furthermore, although medical therapy may delay expansion of the descending aorta, it fails to enhance the remodeling process. Subsequent elective late aortic interventions are required in 25% to 30% of patients for aneurysm expansion, extension of the progressive dissection, and other related complications arising from the unresolved dissection process (21, 22 Values are % (n at risk).
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A U G U S T 2 0 1 3 : 8 7 6 -8 2 type B dissection (18) . The present analysis at 5 years seems to corroborate a long-term benefit of endovascular repair over medical management alone, despite an initially higher risk category of TEVAR patients, demonstrated by the 41.5% of cases who were considered complicated at admission. The 5-year Kaplan-Meier mortality estimates were significantly lower for patients managed with interventional techniques (15.5% TEVAR vs. 29.0% medical), despite the initially higher risk profile due to the complicated nature of the dissection patients subjected to TEVAR. The IRAD database analysis, which reflects the "realworld" scenario, supports the premise of long-term advantages in survival with selected endovascular treatment as compared with open surgical strategies and/or medical management alone. It is important to emphasize also that extension of dissection observed in follow-up may not be a complication of stent-graft treatment, but rather the progressive nature of the aortic disease continuum (28, 29) . Study limitations. Several considerations are important in interpreting the results of this study. The IRAD cohort includes patients referred to and treated at centers specializing in aortic disease; therefore, the results may not reflect management of patients treated at community hospitals. Patients were not randomized to a predetermined treatment strategy, but subjected to contemporary best therapy at each center; therefore, results could be partially related to selection bias. Most importantly, as with all retrospective observational studies, the database is subject to referral bias, and information on complications and cause of death may potentially reflect slightly different data interpretation.
Conclusions
Historical data have supported the use of medical therapy in patients who survived an acute type B aortic dissection. In IRAD, a subgroup of acute type B dissection patients treated with endovascular repair showed better 5-year survival compared with patients with medical therapy alone. If longterm follow-up and randomized studies support these preliminary data, it appears that uncomplicated type B aortic dissection could become an indication for early elective endovascular stent grafting.
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